Penumbra shareholders approve merger with Boston Scientific; vote 28.6M for, 85k against

1) Merger Proposal . A proposal to adopt the Agreement and Plan of Merger (the “Merger Agreement”), dated January 14, 2026, by and among the Company, Boston Scientific Corporation, a Delaware corporation (“Parent”), and Pinehurst Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), pursuant to which Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving as a wholly owned subsidiary of Parent, was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 28,564,786 85,334 15,813 N/A

3) Adjournment Proposal . A proposal to adjourn or postpone the Special Meeting, if necessary or appropriate, to solicit additional proxies if, immediately prior to such adjournment or postponement, there were not sufficient votes to approve the Merger Proposal or to ensure that any supplement or amendment to the Proxy Statement was timely provided to the Company's stockholders, received the following votes; however, because the Merger Proposal was approved, the Adjournment Proposal was not necessary. Votes For Votes Against Abstentions Broker Non-Votes 27,309,440 1,295,803 60,690 N/A

2) Advisory Compensation Proposal . A proposal to approve, on a non-binding, advisory basis, the compensation that the Company’s named executive officers will or may be eligible to receive in connection with the Merger, was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 27,811,605 765,399 88,929 N/A